Femoston
Life is complicated…
…HRT doesn’t have to be
Femoston® is indicated for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses1,2
Femoston®-conti is indicated for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses 3,4
Femoston® Advantages
Well-Ballanced Oestrogen and Progestogen Combination
Femoston® contains oestradiol (a body identical oestrogen, structurally indentical to endogenous oestrogen) and dydrogesterone, a progestogen with fewer androgenic or metabolic side effects compared to older ones like norethisterone. 1,5
Suitable for Perimenopausal and Menopausal Women
The Femoston® range is available in sequential combined (Femoston®) and continuous combined preparations (Femoston®-conti) covering a wide range of doses (standard to ultra-low). 1,5
Once – Daily Dosing Convenience
Convenience of once – daily fixed oral dose preparation. 1,4
Endometrial Protection
Femoston® has been shown to provide effective endometrial protection with an acceptable bleeding and tolerability profile. 6,8
Cardiovascular Risk
Femoston® is not associated with a higher risk of cardiovascular events than use of other HRT.* 9
*Oral conjugated equine oestrogen (CEE) + norgestrel, oral oestradiol (valerate) + norethisterone (acetate), or oral CEE + medroxyprogesterone acetate.
Breast Cancer & VTE Risk
Dydrogesterone is associated with a lower breast cancer and VTE risk compared to other synthetic progestogens.* 10, 12
*Norethisterone acetate (NETA), Medroxyprogesterone acetate (MPA), (levo)norgesterol.
Vasomotor Symptom Control
Femoston®-conti has been shown to have effective vasomotor symptom control compared to placebo. Both Femoston®-conti 0.5/2 mg and 1/5mg were well tolerated (Full analysis sample, n=305). 13
Osteoporosis Prevention
Femoston®-conti 1mg/5mg, Femoston® 1/10mg and 2/10mg film-coated tablets are also indicated for the prevention of osteoporosis in postmenopausal women. 1,2,4
Bleeding Control
The porcentage of women with amenorrhoea increased from 81.1% and 74.6% at 3 months to 91.4% and 88.2% in months 10-12 in women receiving E 0.5mg/D 2.5mg and E 1mg/D 5mg, respectively compared to placebo (81.5%). N=313. 13
Breast cancer & VTE risk
Dydrogesterone is associated with a lower breast cancer and VTE risk compared to other synthetic progestogens.* 10-12
*Norethisterone acetate (NETA), Medroxyprogesterone acetate (MPA), (levo)norgesterol
Why Choose Oral HRT For Your Patients?
Oral vs transdermal adherence and discontinuation rates
Retrospective, cross-sectional study of SAIL primary and secondary care data in Wales (n=103, 114), aiming to identify factors influencing adherence to transdermal and oral HRT within 1 year of initation, shows 14
Better adherence
- Oral HRT is significantly more like to be adhered to past 1 year than transdermal formulations. 14
- Better adherence rates with oral HRT could be explained by the inconvenience of transdermal formulations or poor absorbency. 14
Lower discontinuation
- Oral HRT has lower discontinuation rates compared with transdermal formulations. 14
- A 48% risk reduction in treatment discontinuation in oral vs transdermal combined regimes (combined patches IRR: 1.00 (n=15,538); combined tablets IRR: 0.52 (n=10,697)).14
Reliable delivery
- A UK real-world study shows one in four women (24,84%) using the highest licensed dose of transdermal oestrogen* (4PE) failed to reach therapeutic oestradiol levels (200 pmol/L) (n=467)6
*Study participants were included if they had been using transdermal estradiol (patch, gel, or spray) for >3 months and had at least one serum estradiol level recorded in the study period.
Oral HRT has better bleeding profile than transdermal formulations 16
More women stay amenorrheic throughout one year with oral HRT compared with transdermal HRT. 16
Systematic review of 45 non head-to-head studies comparing cumulative amenorrhea rates (proportions of women remaining amenorrheic) from cycle 1 to cycle 12/13 as reported for different HRT products approved for treatment of postmenopausal symptoms in North America and Europe. 16
Femoston® range
The Femoston® range is available in sequential combined (Femoston®) and continuous combined preparations (Femoston®-conti) covering a wide range of doses (standard to ultra-low). 1-4
Sequential
Femoston® 1mg /10mg
Estradiol / Dydrogesterone
Femoston® 2mg /10mg
Estradiol / Dydrogesterone
For oestrogen deficiency symptoms in postmenopausal women at least 6 months after las menses. 1,2
Continuous
Femoston® – conti 1mg /5mg
Estradiol / Dydrogesterone
Femoston® – conti 0.5mg /2.5mg
Estradiol / Dydrogesterone
(Ultra low dose)
For oestrogen deficiency symptoms in postmenopausal women at least 12 months after las menses. 3,4
Abbreviations: CEE, conjugated equine estrogens; DRSP, drospirenone; E2, 17-β-estradiol; EE, ethinyl estradiol; HRT, hormone replacement therapy; LNG, levonorgesterel; MPA, medroxyprogesterone acetate; NETA, norethisterone acetate; P4, progesterone; PE, pumps equivalent; SAIL, Secure Anonymised Information Linkage (database); VTE, venous thromboembolism.
References: 1. Femoston® 1mg/10mg Summary of Product Characteristics. 2.Femoston® 2/10mg Summary of Product Characteristics. 3.Femoston®-conti 0.5mg/2.5mg Summary of Product Characteristics. 4. Femoston®-conti 1mg/5mg Summary of Product Characteristics. 5. Binkowska M and Woron J. Prz Menopauzalny 2015 Jun 22;14(2):134–143. 6. Ferenczy A et al. Climacteric 2002; 5(1):26–35. 7. Quereux C et al. Maturitas. 2006; 53(3):299–305. 8. Bergeron C et al. Maturitas. 2010; 66(2):201–205. 9. Schneider C et al. Clinacteric.2009;12(5):445–453. 10. Fournier A et al. Breast Cancer Res Treat. 2008;107:103–11. 11. Baber RJ et al. IMS Writing Group. Climacteric. 2016;19(2):109-50. 12. Collaborative Group on Hormonal Factors in Breast Cancer. The Lancet. 2019;394(10204):1159–1168. 13. Stevenson JC, et al. Maturitas. 2010;67(3):227–232. 14. Andrews R et al. Int J Obstet Gynecol. 2025;0:1–12. 15. Glynne S et al. Menopause. 2025;32:103–1117. 16. Pickar JH et al. Climacteric. 2020;23:550–558
